Omecamtiv Mecarbil

Healio and Cardiology Today have aggregated the top cardiology headlines of March 2023.

The FDA has issued a complete response letter to Cytokinetics for omecamtiv mecarbil, an investigational, selective small molecule cardiac myosin activator for treatment of HF with reduced ejection fraction, according to a press release.

Healio and Cardiology Today have compiled a list of the most-read headlines of December 2022 in cardiology.

Healio and Cardiology Today have aggregated a list of the top headlines of 2022 in heart failure and transplantation.

An FDA advisory committee voted 8-3 against supporting the approval of the HF drug omecamtiv mecarbil, with panelists citing a small observed benefit for a limited group of patients.

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported.

In a post hoc analysis of the GALACTIC-HF trial, omecamtiv mecarbil reduced the primary endpoint of time to first HF event or CV death among patients with severe HF.

Omecamtiv mecarbil was safe and effective compared with placebo in Black patients with HF with reduced ejection fraction, according to new data from GALACTIC-HF presented at the Heart Failure Society of America Annual Scientific Meeting.